March 27, 2017
In a research effort that merged genetics, physics and information theory, a team at the schools of medicine and engineering at The Johns Hopkins University has added significantly to evidence that large regions of the human genome have built-in variability in reversible epigenetic modifications made to their DNA. In a report on the research published […]
March 9, 2017
Working as part of an international research consortium, a multidisciplinary team at the Johns Hopkins University has completed the design phase for a fully synthetic yeast genome.
February 24, 2017
Winston Timp, an assistant professor of biomedical engineering, supervised research on new computational software that determines if a human DNA sample includes an epigenetic add-on linked to cancer and other health conditions.
January 26, 2017
Johns Hopkins researchers report that a new peptide holds promise for improving treatment for degenerative retinal diseases, such as age-related macular degeneration, diabetic macular edema and diabetic retinopathy. These vascular diseases often result in central vision loss as blood vessels grow into tissues at the back of the eye, where such growth should not occur.
January 23, 2017
Jordan Green, associate professor of biomedical engineering, and his colleagues have figured out a noninvasive way to release and deliver concentrated amounts of a drug to the brain of rats in a temporary, localized manner using ultrasound.
January 19, 2017
A multicenter team of researchers reports that a full genomic analysis of tumor samples from a small number of people who died of pancreatic cancer suggests that chemical changes to DNA that do not affect the DNA sequence itself yet control how it operates confer survival advantages on subsets of pancreatic cancer cells. Those advantages, the researchers say, let such cancer cells thrive in organs like the liver and lungs, which receive a sugar-rich blood supply.
January 7, 2017
Jordan Green, associate professor of biomedical engineering, and Jonathan Schneck, professor of pathology, both at the School of Medicine, have learned that by combining a biomimetic particle along with a more traditional immunotherapy they could lengthen the lives of mice with skin cancer better than either treatment alone. Both approaches focus on activating the rodent immune system killer T cells — white blood cells that fight infection and other invaders.